Overview

A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months. KX2-391 given orally twice a day for 6 months will be evaluated for its ability to delay/prevent disease progression in patients who have not had prior chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Kinex Pharmaceuticals Inc
Kinex Pharmaceuticals Inc.

Treatments:

Tirbanibulin